OncoSil Medical Limited (ASX: $OSL) Pancreatic cancer treatment device company reported its half-yearly performance recently, and there are many significant milestones achieved by the company before diving into the report further, let’s see what the CEO & Managing Director Nigel Lange said: “The December 2023 half saw further significant progress made in our efforts to commercialise the OncoSil device. The device’s worth as a treatment of locally advanced unresectable pancreatic cancer, in combination with gemcitabine-based chemotherapy, continued to be reinforced – and this momentum is expected to build further over coming months as patients continue to be onboarded by the PANCOSIL and TRIPP studies. While this positive reinforcement is occurring on the studies front, OncoSil has, at the same time, further penetrated key addressable markets, with more hospitals now using the device.” Yes, positive commentary from the CEO, this kind of optimism of the management tells about the growth of the company in future.